Yousif Capital Management LLC Has $14.49 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Yousif Capital Management LLC lowered its stake in shares of Boston Scientific Co. (NYSE:BSX) by 3.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 250,693 shares of the medical equipment provider’s stock after selling 9,476 shares during the period. Yousif Capital Management LLC’s holdings in Boston Scientific were worth $14,493,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in BSX. BSW Wealth Partners boosted its position in Boston Scientific by 2.3% during the fourth quarter. BSW Wealth Partners now owns 7,398 shares of the medical equipment provider’s stock worth $428,000 after purchasing an additional 165 shares during the period. Valley National Advisers Inc. raised its holdings in Boston Scientific by 2.3% in the 4th quarter. Valley National Advisers Inc. now owns 7,526 shares of the medical equipment provider’s stock valued at $435,000 after acquiring an additional 170 shares during the period. Whitaker Myers Wealth Managers LTD. boosted its holdings in shares of Boston Scientific by 4.6% during the fourth quarter. Whitaker Myers Wealth Managers LTD. now owns 4,093 shares of the medical equipment provider’s stock worth $237,000 after acquiring an additional 179 shares during the period. Brighton Jones LLC grew its position in shares of Boston Scientific by 5.4% in the third quarter. Brighton Jones LLC now owns 3,999 shares of the medical equipment provider’s stock valued at $211,000 after purchasing an additional 205 shares during the last quarter. Finally, Altfest L J & Co. Inc. increased its stake in shares of Boston Scientific by 1.6% during the third quarter. Altfest L J & Co. Inc. now owns 13,298 shares of the medical equipment provider’s stock worth $702,000 after purchasing an additional 208 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded up $3.97 during midday trading on Wednesday, hitting $72.96. 11,329,377 shares of the company traded hands, compared to its average volume of 6,474,063. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $74.39. The stock has a market cap of $107.04 billion, a price-to-earnings ratio of 68.38, a PEG ratio of 2.38 and a beta of 0.78. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32. The firm’s fifty day moving average price is $67.39 and its 200-day moving average price is $60.19.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, topping the consensus estimate of $0.51 by $0.04. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. The business had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.59 billion. During the same period last year, the company earned $0.45 EPS. As a group, sell-side analysts forecast that Boston Scientific Co. will post 2.25 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Edward J. Ludwig sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the sale, the director now owns 41,374 shares of the company’s stock, valued at approximately $2,690,551.22. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Edward J. Ludwig sold 7,000 shares of Boston Scientific stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total transaction of $455,210.00. Following the sale, the director now directly owns 41,374 shares in the company, valued at approximately $2,690,551.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $66.89, for a total transaction of $467,092.87. Following the completion of the sale, the executive vice president now directly owns 56,508 shares in the company, valued at approximately $3,779,820.12. The disclosure for this sale can be found here. Insiders sold 50,979 shares of company stock valued at $3,418,529 over the last quarter. Insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

BSX has been the subject of several recent research reports. Royal Bank of Canada boosted their price target on Boston Scientific from $70.00 to $78.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. TD Cowen raised their price target on shares of Boston Scientific from $65.00 to $77.00 and gave the stock an “outperform” rating in a research report on Thursday, March 7th. Mizuho raised shares of Boston Scientific from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $65.00 to $80.00 in a report on Thursday, February 1st. Needham & Company LLC raised their target price on shares of Boston Scientific from $60.00 to $71.00 and gave the stock a “buy” rating in a report on Thursday, February 1st. Finally, Argus boosted their price target on Boston Scientific from $69.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Two investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $68.50.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.